Atlas Trials

Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines

Clinical trial NCT06937944 · RECRUITING

Trial details

NCT number
NCT06937944
Sponsor
JHM BioPharma (Tonghua) Co. , Ltd.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Moderate to Severe Glabellar Lines
Start date
2025-04-30
Primary completion
2026-02-09
Enrollment
669

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.